To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

NCT06165965 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult

Interventions

DRUG: SGLT2 inhibitor

Sponsor

Jeil Pharmaceutical Co., Ltd.